Predictive analytics specialist Viscovery reports increased return on sales for business year 2013
[News Viscovery]
Vienna / Austria, 28 March 2014 With a further increase in sales compared to the previous year and a return on sales of 15%, Viscovery continued on the road to success in 2013. Licenses and services accounted for more than 75% of the total sales. Particularly dynamic growth was seen for business in the Asia-Pacific region, with an increasing trend toward the end of the year for Europe as well.
New customers acquired in 2013 include the Toyota Motor Corporation, Aisin Infotex, and Nippon Medical School. Collaboration with the Deloitte Group continued to grow: in addition to the many country-specific organizations, Deloitte Anjin and Deloitte Touche Tohmatsu chose the Viscovery predictive analytics tool for their professional services. Additional research institutions have newly licensed Viscovery software, including the Research Institute of Shizuoka, Kawasaki Geological Engineering, Kyoto University, University of Piraeus, University of Science Malaysia, and Tohoku University.
The focus for services in 2013 was on the life sciences. In particular, projects in collaboration with the parent company, Biomax Informatics AG, intensified further. Together with the Dutch Centre of Expertise for Chronic Organ Failure (CIRO), research results on comorbidity achieved with Viscovery were published in a well-respected journal (see www.atsjournals.org).
As the result of years of development, version 6.0 of the Viscovery Data Mining Suite was released in the previous year. In addition to many improvements in the user interface, this version provides new functions for the clustering and profiling of high-dimensional data, a feature that is required for explorative analysis of biomedical and textual data.
Viscovery launches major release of its visual data-mining platform
[News Viscovery]
Vienna / Austria, 15 May 2013 Data-mining specialist Viscovery unveiled the latest major release of the Viscovery ® Software Suite, designed to help customers uncover high-value insights in complex data sets. Viscovery version 6.0 offers numerous enhancements, a more intuitive user interface, and several new features with particular importance for biomedical and genetic analysis. The new version is the culmination of years of software development.
Building on Viscovery’s unique, patented technology for explorative analysis and statistical modeling of complex data, many of the new features emerged from the company’s successful expansion into the life sciences. The Group comparison feature and the Cluster characteristics feature have proven to be particularly crucial for data-mining customers in bioscience and medical research.
Other improvements are designed to monitor process states, display images of clustered objects directly over the analytical model, and provide analytical features, such as a correlation- independent measure for the influence of individual attributes on a target attribute. A re-designed graphical interface, enhanced workflow management and other usability improvements round out the latest version of the Viscovery suite. Download a summary of the new features from www.viscovery.net/data-sheets.
“One of the things customers like most about the new release is that the identification of interesting attributes in very high-dimensional data comes with a multiple testing correction which helps avoid false positives, particularly when the data being analyzed contain thousands of variables,” says Dr. Gerhard Kranner, CEO of Viscovery Software. “By revealing high-value insights, whether they are in customer analytics or biomarker identification, without the time and cost of traditional analysis, Viscovery gives organizations the ability to quickly and intuitively extract critical knowledge from complex data sets.”
Viscovery version 6.0 is a full major release and is available immediately. Existing customers are already being upgraded. A free trial version is available at www.viscovery.net.
Data-Mining Specialist Viscovery Reports Profits for 2012
[News Viscovery]
Vienna / Austria, 14 March 2013 Vienna-based Viscovery achieved good results again in 2012. With licenses and services making 85% of the business volume, profits have clearly exhibited stable growth since 2011. Above average increase was realized in the Asia-Pacific region. SOM business (data mining using self- organizing maps) continues in 2013 to take hold in a wider international market.
New customers acquired in 2012 include Japan Aerospace, Honda R&D, the online-game provider Funstage, the Ministry of Finance in Singapore, and the loyalty-program specialist Pinpoint, among others. Meanwhile, Deloitte have expanded their implementation of Viscovery software for their professional services into more than 10 countries. Numerous research institutes and universities continued to work with Viscovery software in 2012, including newcomers Louisiana State University Health Sciences Center, Michigan Technological University, Tokyo University, and University of Southern Queensland.
In cooperation with parent company Biomax Informatics AG, projects in the Life Science were further expanded particularly in the areas of medical research and biomarker identification. Thus, Viscovery provided data mining software and consulting to the new CIRO+ data center in the Netherlands — one of the most outstanding centers of excellence in Europe for diagnosis and treatment of chronic obstructive pulmonary disease.
Viscovery successfully expands data mining business to life sciences
[News Viscovery]
Vienna / Austria, April 2012 Data mining-specialist Viscovery Software GmbH continues to develop its data-mining business in the life science branch. In collaboration with mother company Biomax Informatics AG, Viscovery is contributing to the establishment of a new data center for CIRO+ in the Netherlands by providing data mining software and consulting. This is the first integrated patient-centric knowledge management system for patient stratification and targeted therapy in chronic obstructive pulmonary disease (COPD).
"The CIRO+ Data Center allows, for the first time, to better understand patient outcome based on systematic pre- and post-assessment data of more than 3,000 patients over the past 6 years with up to 6,000 clinical data points captured for each patient. The impact of being able to exploit clinical knowledge effectively using state-of-the-art technology cannot be overestimated. This applies to both improved patient care and better management of treatment costs”, as Prof. Wouters, Chairman Board of Directors CIRO+, explained at the announcement of the CIRO+ Data Center launch.
In addition to this project, the Viscovery data-mining approach using SOM methodology is supporting medical research with identification of possible candidates for biomarkers by allowing clinical data to be examined and clustered with genetic data. Recently, projects in drug efficacy as well as the classification of clinical data to distinguish responsive and unresponsive patients have been successfully completed.
The international Cancermotisys research project (biomax.com/project/cancermotisys), examining the specific effects of stomach cancer drugs, is in its third year and close to completion. Viscovery has been involved in examining the relationship between cancer cell motility and genetic expression data.